OMEICOS Therapeutics Nets €6.2M in Series A Funding
April 21, 2015
OMEICOS Therapeutics, a biopharmaceutical company developing small molecule therapeutics for the prevention and treatment of cardiovascular diseases, has raised €6.2 million of Series A funding. The round was led by Vesalius Biocapital and included participation from SMS Group, High-Tech Gründerfonds, IBB Beteiligungsgesellschaft and KfW Group. OMEICOS' lead candidate is envisioned for oral, once-daily treatment for patients with paroxysmal and persistent atrial fibrillation, with and without structural heart disease, for maintenance of sinus rhythm.